Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07164170 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 25, 2025 to Sep 22, 2025 · Site details revised at 17 of 17 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Oct 25, 2025 to Sep 22, 2025
    • Site details revised at 17 of 17 sites
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, open-label phase 2 study that will enroll KRASG12C mutated patients with locally advanced or metastatic NSCLC, receiving treatment (ABSK043 in combination with Glecirasib) in a 21-day combination cycle.
Trial Details
NCT Number NCT07164170
Lead Sponsor Abbisko Therapeutics Co, Ltd
Conditions Non-Small Cell Lung Cancer
Enrollment 86 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov